PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Infliximab - Graft versus Host Disease (GVHD)
PAD Profile : Infliximab - Graft versus Host Disease (GVHD) Important
Brand Names Include :
Inflectra, Remicade, Remsima
Important Information :
Specialist centres only
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
Other Indications
- Ankylosing spondylitis
- Inflammatory bowel disease
- Psoriasis
- Psoriatic arthritis
- Rheumatoid arthritis
- Immunotherapy related colitis
- Inflammatory bowel disease - paediatric use
- Uveitis
- Connective tissue disease
- Behcet's syndrome
- Pouchitis
Additional Documents
No additional documents returned.
Committee Recommendations
Date
Committee Name
Narrative
16 April 2018
Not Set
This drug / device falls under the responsibility of NHS England Specialised Commissioning and should therefore not be prescribed in Primary Care.
Treatment should remain with the specialist (RED) hospital only drug.
GPs should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.
Associated BNF Codes
01. Gastro-Intestinal System
01.05.03. Drugs affecting immune response
10. Musculoskeletal and Joint Diseases
10.01.03. Rheumatic disease suppressant drugs
13. Skin
13.05.03. Drugs affecting the immune response